You haven't searched anything yet.
ALX Oncology Inc. (ALX) is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway. Our lead candidate, evorpacept (ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. For more information about us, please visit www.alxoncology.com.
ALX is looking for a highly motivated Associate Director/Director, Translational Oncology with scientific and clinical expertise in immune oncology to expand our Translational Oncology team. The candidate will work within a multi-disciplined Clinical Development team and will be responsible for contributing to the design and implementation of translational and clinical biomarker strategy for the company’s growing oncology portfolio.
Responsibilities:
Qualifications:
Hybrid work model acceptable (i.e., part-time in South San Francisco with flexibility to work part-time from home). This may also include our lab in Palo Alto.
Salary Range:
Associate Director: $178,000-$205,000
Director: $215,000-$245,000
ALX Oncology is an equal opportunity employer. All applicants should be legally entitled to work for any employer in the US. Title and salary are commensurate with experience.Our compensation program includes competitive salary, equity participation and attractive bonus incentives.
Full Time
$88k-111k (estimate)
02/02/2024
06/30/2024
alxoncology.com
BURLINGAME, CA
25 - 50
2015
JAUME PONS
<$5M